Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Mar 5]. Available from : https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html
   Google Scholar
• [cited 2020 Mar 2]. Available from: https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet.html
   Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):120858.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Sept 25]. Available from: https://www.drugs.com/history/prolia.html
   Google Scholar
• Peters S, Clézardin P, Márquez-Rodas I, et al. The RANK–RANKL axis: an opportunity for drug repurposing in cancer? Clin Transl Oncol. 2019;21:977–991.
   PubMed Web of Science ®Google Scholar
• Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012;18(2):326–335.
   PubMed Web of Science ®Google Scholar
• Martin TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop. 2013;4(4):186–197.
   PubMedGoogle Scholar
• Renema N, Navet B, Heymann MF, et al. RANK–RANKL signalling in cancer. Biosci Rep. 2016;36(4):e00366.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Mar 7]. Available from: https://www.drugs.com/history/xgeva.html
   Google Scholar
• Coleman R. Management of bone metastases. Oncologist. 2000;5:463–470.
   PubMedGoogle Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–1867.
   PubMed Web of Science ®Google Scholar
• De Castro J, García R, Garrido P, et al. Therapeutic potential of denosumab in patients with lung cancer: beyond prevention of skeletal complications. Clin Lung Cancer. 2015;16(6):431–446
   PubMed Web of Science ®Google Scholar
• D’Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6(3):101‐114
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7:1823–1829.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–1132.
   PubMed Web of Science ®Google Scholar
• Peters S, Meylan E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol. 2013;25:137–144.
   PubMed Web of Science ®Google Scholar
• Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–192.
   PubMed Web of Science ®Google Scholar
• Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175–179
   PubMed Web of Science ®Google Scholar
• Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(12):2075–2080.
   PubMed Web of Science ®Google Scholar
• Cheng ML, Fong L. Effects of RANKL-Targeted therapy in immunity and cancer. Front Oncol. 2014;3:329.
   PubMedGoogle Scholar
• Ahern E, Smyth MJ, Dougall WC, et al. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. Nat Rev Clin Oncol. 2018;15(11):676–693.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–107
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102
   PubMed Web of Science ®Google Scholar
• Xiang L, Gilkes DM. The contribution of the immune system in bone metastasis pathogenesis. Int J Mol Sci. 2019;20(4):999.
   Web of Science ®Google Scholar
• Chu GC, Chung LW. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014;33(2–3):497–509.
   PubMed Web of Science ®Google Scholar
• Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–622.
   PubMed Web of Science ®Google Scholar
• Beleut M, Rajaram RD, Caikovski M, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA. 2010;107:2989–2994.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Soyal SM, Li J, et al. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. Faseb J. 2010;24:4408–4419.
   PubMed Web of Science ®Google Scholar
• Jones DH, Nakashima T, Sanchez OH. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084):692–696.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang Z, Ma Y, et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med. 2016;22(5):539–546
   PubMed Web of Science ®Google Scholar
• Yue Z, Yuan Z, Zeng L, et al. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells. Faseb J. 2018;32(5):2422–2437
   PubMed Web of Science ®Google Scholar
• Tan B, Shi X, Zhang J, et al. Inhibition of Rspo-Lgr4 facilitates checkpoint blockade therapy by switching macrophage polarization. Cancer Res. 2018;78(17):4929–4942
   PubMed Web of Science ®Google Scholar
• Zheng X, Turkowski K, Mora J, et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(29):48436–48452
   PubMedGoogle Scholar
• Sigl V, Owusu-Boaitey K, Joshi PA, et al. RANKL/RANK control Brca1 mutation. Cell Res. 2016;26(7):761–774
   PubMed Web of Science ®Google Scholar
• Nolan E, Vaillant F, Branstetter D, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016;22(8):933–939
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Steger GG, et al. Austrian breast and colorectal cancer study group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer(ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:339–351.
   PubMed Web of Science ®Google Scholar
• Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817–6830.
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GT, Sherrill TP, Cheng DS, et al. Blackwell TS Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A. 2007;104(47):18514–18519.
   PubMed Web of Science ®Google Scholar
• Deng J, Fujimoto J, Ye XF, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila). 2010;3(4):424–437.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010;17(1):89–97.
   PubMed Web of Science ®Google Scholar
• Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009;462(7269):104–107.
   PubMed Web of Science ®Google Scholar
• Wong KK, Jacks T, Dranoff G. NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila). 2010;3(4):403–405.
   PubMed Web of Science ®Google Scholar
• Chen W, Li Z, Bai L, et al. NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 2011;16:1172–1185.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Lockwood WW, Deléhouzée S, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest. 2011;121(10):4095–4105.
   PubMed Web of Science ®Google Scholar
• Faget J, Contat C, Zangger N, et al. RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma. J Thorac Oncol. 2017;13(3):387–398.
   PubMed Web of Science ®Google Scholar
• Rao S, Sigl V, Wimmer RA, et al. RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Genes Dev. 2017;31(20):2099–2112
   PubMed Web of Science ®Google Scholar
• Liede A, Hernandez RK, Wade SW, et al. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology. 2018;7:e1480301
   PubMed Web of Science ®Google Scholar
• Ahern E, Harjunpää H, O’Donnell JS, et al. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology. 2018;7:e1431088.
   PubMed Web of Science ®Google Scholar
• Chen LM, Kuo CH, Lai TY, et al. RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem. 2011;112:933–941.
   PubMed Web of Science ®Google Scholar
• Peng X, Guo W, Ren T, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361
   PubMed Web of Science ®Google Scholar
• Last Updated: Wednesday, 29 January 2020 09:42. [cited 2020 Jun 16]. Available from : http://www.etop.eu.org/Searched for SPLENDOUR.
   Google Scholar
• Peters S, Danson SJ, Hasan B, et al. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the ETOP and EORTC SPLENDOUR trial [abstract 1385PD]. Ann Oncol. 2018;29:viii493–viii547.
   Web of Science ®Google Scholar
• Curioni-Fontecedro A, Husmann L, Soldini D, et al. Primary non–small-cell lung cancer response upon treatment with denosumab. Lung Cancer. 2013;82:506–508.
   PubMed Web of Science ®Google Scholar
• Ahern E, Cubitt A, Ballard E, et al. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials. 2019;20(1):753
   PubMed Web of Science ®Google Scholar
• [cited 2020 Jan]. Available from : https://www.xgeva.com/hcp/solid-tumors/pivotal-trial-safety/
   Google Scholar
• Laskowski LK, Goldfarb DS, Howland MA, et al. A RANKL Wrinkle: denosumab-Induced Hypocalcemia. J Med Toxicol. 2016;12(3):305–308
   PubMed Web of Science ®Google Scholar
• Pittman K, Antill YC, Goldrick A, et al. Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol. 2017;13(4):266–276
   PubMed Web of Science ®Google Scholar
• Yerram P, Kansagra S, Abdelghany O. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis. J Oncol Pharm Pract. 2016;23(3):179–184.
   PubMed Web of Science ®Google Scholar
• Jalleh R, Basu G, Le Leu R, et al. Denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep Nephrol. 2018;2018:7384763.
   PubMedGoogle Scholar
• Kinoshita Y, Arai M, Ito N, et al. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocr J. 2016;63(5):479–484
   PubMed Web of Science ®Google Scholar
• Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51(13):1812–1821
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Nagai T, Sakamoto K, et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag. 2016;12:1831–1840.
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36(10):1622–1626
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/safety/medwatch/safetyinformation/ucm303740.htm http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm356528.htm.
   Google Scholar
• Migliorati C Recognition and management of osteonecrosis of the jaw. 2015 MASCC/ISOO International Symposium. Parallel Session PS11. Presented June 26, 2015.Copenhagen, Denmark
   Google Scholar
• Lombard T, Neirinckx V, Rogister B, et al. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016;2016:8768162.
   PubMed Web of Science ®Google Scholar
• Nifosì AF, Zuccarello M, Nifosì L, et al. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019;45(1):3–8
   PubMed Web of Science ®Google Scholar
• Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23
   PubMed Web of Science ®Google Scholar
• Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol. 2018;36:501.
   Web of Science ®Google Scholar
• Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016;27:367–375.
   PubMed Web of Science ®Google Scholar
• Svejda B, Muschitz C, Gruber R, et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166(1–2):68–74
   PubMed Web of Science ®Google Scholar
• Coropciuc RG, Grisar K, Aerden T, et al. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg. 2017;55(8):787–792
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment inpostmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–523.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab–a case report. Acta Orthop. 2014;85(1):6–7.
   PubMed Web of Science ®Google Scholar
• Toro G, Ojeda-Thies C, Calabrò G, et al. Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord. 2016;17:227.
   PubMed Web of Science ®Google Scholar
• McClung MR. Cancel the denosumab holiday. Osteoporos Int. 2016;27:1677–1682.
   PubMed Web of Science ®Google Scholar
• Lamy O, Stoll D, Aubry-Rozier B, et al. Stopping denosumab. Curr Osteoporos Rep. 2019;17(1):8–15
   PubMed Web of Science ®Google Scholar
• von Keyserlingk C, Hopkins R, Anastasilakis A, et al. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum. 2011;41(2):178–186
   PubMed Web of Science ®Google Scholar
• Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singapore Med J. 2019;60(7):364–378.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Toriz NH, et al. For the Denosumab HALT prostate cancer study group C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–755.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–4882.
   PubMed Web of Science ®Google Scholar
• Tovazzi V, Dalla Volta A, Pedersini R, et al. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis. Future Oncol. 2019;15:2319–2321
   PubMed Web of Science ®Google Scholar
• Timotheadou E, Kalogeras KT, Koliou GA, et al. Evaluation of the prognostic value of RANK, OPG, and RANKL mRNA expression in early breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Transl Oncol. 2017;10:589–598.
   PubMed Web of Science ®Google Scholar
• Owen S, Ye L, Sanders AJ, et al. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33:199–206.
   PubMed Web of Science ®Google Scholar
• Bhatia P, Sanders MM, Hansen MF. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res. 2005;11:162–165.
   PubMed Web of Science ®Google Scholar
• Park HS, Lee A, Chae BJ, et al. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol. 2014;110:807–812.
   PubMed Web of Science ®Google Scholar
• Papanastasiou AD, Sirinian C, Kalofonos HP. Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res. 2012;14:R112
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822
   PubMed Web of Science ®Google Scholar
• Deiana L, Claps M, Berruti A. Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients? J Thorac Oncol. 2013;8(8):e79.
   PubMed Web of Science ®Google Scholar
• Weichhaus M, Chung ST, Connelly L. Osteoprotegerin in breast cancer: beyond bone remodeling. Mol Cancer. 2015;14:117.
   PubMed Web of Science ®Google Scholar
• Corrales L, Scilla K, Caglevic C, et al. Immunotherapy in lung cancer: a new age in cancer treatment. Adv Exp Med Biol. 2018;995:65–95.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Yagita H, McArthur GA. Combination Anti-CTLA-4 and Anti-RANKL in metastatic melanoma. J Clin Oncol. 2016;34(12):e104–106.
   PubMed Web of Science ®Google Scholar
• Deligiorgi MV, Panayiotidis MI, Trafalis DT. Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology? JBUON. 2020;25(1):1–14.
   Google Scholar
• Dougall WC, Roman Aguilera A, Smyth MJ. Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity. Clin Transl Immunology. 2019 8;27(10):e01081.
   Google Scholar
• Yuan M, Huang L, Chen J, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Sig Transduct Target Ther. 2019;4:61.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36:536–542.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen H, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307–1316.
   PubMed Web of Science ®Google Scholar
• Furugaki K, Moriya Y, Iwai T, et al. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis. 2011;28(7):649‐659
   PubMed Web of Science ®Google Scholar
• Okano Y, Nishio M. Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium. 2008;18(4):527–533.
   PubMedGoogle Scholar
• Miwa M, Okuma Y, Kashima J, et al. Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab. Eur Respir J. 2017;50:PA2046.
   Web of Science ®Google Scholar
• Ferguson J, Wilcock DJ, McEntegart S, et al. Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. Pigment Cell Melanoma Res. 2019;33:74–85.
   PubMed Web of Science ®Google Scholar
• Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157.
   PubMedGoogle Scholar
• [cited 2020 Jun 16]. Available from: https://clinicaltrials.gov/
   Google Scholar